HTA59 Budget Impact Analysis Of Migalastat Incorporation vs. Enzyme Replacement Therapies For Fabry Disease: Validation of a Cost-Assessment Tool In Brazilian Private Healthcare System
Abstract
Authors
Joao Paulo Dos Reis Neto JULIANA BUSCH